Evaluation
*
*

Thinking about the impact of this session on your patients, please offer an estimate of the:

*
%
*
/month
*
1 (Disagree)2345 (Agree)
Describe the latest WHO disease definitions for diagnosing myeloid malignancies
Recall the mechanisms of action for novel therapies for AML
Summarize the clinical relevance of molecular mutations in AML, including FLT3 and IDH2
Identify germline mutations in patients with predisposition for AML
*
1 (Low)2345 (High)
Sandra E. Kurtin, PhDc, ANP-C, AOCN
Gabrielle Zecha, PA-C, MHA
*
*